The identified biomarkers, T helper cell CD36 and monocyte GLUT1, showed significant predictive capability in both drug-naïve and medicated schizophrenia patients, as well as in a trans-diagnostic psychiatric patient cohort, suggesting their potential clinical relevance. The gene discussed is CD36; the disease is schizophrenia.